ロード中...
Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
LESSONS LEARNED. Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study. Pharmacokinetics characteristics in Chinese patients were similar to those in other populations. Immunogenicity was not detected. No efficacy conclusion c...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5469595/ https://ncbi.nlm.nih.gov/pubmed/28465370 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0137 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|